Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703162 | 0.73 | ABCC1 (0.49) | ABCC1ALOX12HTTLMNAGAA | |
| SCHEMBL12011131 | 0.70 | ABCC1 (0.48) | ABCC1ALOX12HTTLMNAGAA | |
| SCHEMBL1702689 | 0.68 | ABCC1 (0.46) | ABCC1ALOX12HTTLMNAGAA | |
| SCHEMBL1702687 | 0.68 | ABCC1 (0.46) | ABCC1ALOX12HTTLMNAGAA | |
| SCHEMBL831379 | 0.68 | GPBAR1 (0.52) | MAPTTSHRMEN1KMT2A | |
| SCHEMBL25412531 | 0.68 | ADORA2B (0.38) | ADORA2BGAAALDH1A1HPGDKDM4E | |
| SCHEMBL30299426 | 0.68 | ADORA2B (0.38) | ADORA2BGAAALDH1A1HPGDKDM4E | |
| SCHEMBL832583 | 0.68 | HPGD (0.41) | LMNAGAAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL10333289 | 0.68 | ALDH1A1 (0.46) | ADORA2BABCC1ALOX12LMNAGAA | |
| SCHEMBL5340705 | 0.66 | HSD17B10 (0.75) | ADORA2BABCC1HTTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143411-B2 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143411-B2 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143411-B2 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| WO-2009033561-A1 | SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | SLC5A6, FABP3, NAPRT | ADORA2B 1971/4885ABCC1 159/4885ALOX12 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.